161 related articles for article (PubMed ID: 37689551)
1. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
[TBL] [Abstract][Full Text] [Related]
2. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
4. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
[TBL] [Abstract][Full Text] [Related]
5. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
Shitara K; Ikeda J; Yokota T; Takahari D; Ura T; Muro K; Matsuo K
Invest New Drugs; 2012 Jun; 30(3):1224-31. PubMed ID: 21350803
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
9. Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
Reinert T; Debiasi M; Bines J; Barrios CH
Breast Cancer Res Treat; 2018 Apr; 168(2):457-465. PubMed ID: 29190006
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
Chirila C; Odom D; Devercelli G; Khan S; Sherif BN; Kaye JA; Molnár I; Sherrill B
Int J Colorectal Dis; 2012 May; 27(5):623-34. PubMed ID: 22076612
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
Beauchemin C; Cooper D; Lapierre MÈ; Yelle L; Lachaine J
Onco Targets Ther; 2014; 7():1101-10. PubMed ID: 24971020
[TBL] [Abstract][Full Text] [Related]
13. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.
Beauchemin C; Johnston JB; Lapierre MÈ; Aissa F; Lachaine J
Curr Oncol; 2015 Jun; 22(3):e148-56. PubMed ID: 26089725
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
16. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Etekal T; Koehn K; Sborov DW; McClune B; Prasad V; Haslam A; Berger K; Booth C; Al Hadidi S; Abdallah AO; Goodman A; Mohyuddin GR
Br J Haematol; 2023 Mar; 200(5):587-594. PubMed ID: 36495317
[TBL] [Abstract][Full Text] [Related]
17. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
Delea TE; Khuu A; Heng DY; Haas T; Soulières D
Br J Cancer; 2012 Sep; 107(7):1059-68. PubMed ID: 22935581
[TBL] [Abstract][Full Text] [Related]
18. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]